Home > Treatment Options > Tumor Suppressors > Clinical Trials >
AR 12
Last Updated: 03/28/17
Status: Determined Ineffective for NF2
Index
- Treatment Information
- Additional Information
Arno Therapeutics', AR12 and AR42 were treatment consideration for NF2. Following Phase 0 mice trials, AR42 was determined to be more likely to be effective. AR12 did not go further in clinical trials.
Treatment Information
| Other Names |
AR12, OSU-HDAR12, HDAR42 |
|---|---|
| Pharmaceutical Company | Arno Therapeutics |
| Prescription Information | Arno Therapeutics - Drug Description |
| Expectation | Change in Meningioma and Schwannoma in CNS |
| Inhibitor | HDAC - Histone deacetylase inhibitors (HDACi), pan-HDAC inhibitor |
|---|
